



JOHN CHAMBERS JOINS H.C. WAINWRIGHT AS PRESIDENT AND HEAD OF INVESTMENT BANKING

NEW YORK, January 8, 2017 – H.C. Wainwright & Co., LLC (“HCW”), the leading investment bank focused on capital markets and equity research in the Life Sciences and Biotechnology sectors, announced today that John W. Chambers has joined the firm as President and Head of Investment Banking. Mr. Chambers will further enhance HCW’s strong reputation as a client-centric organization and accelerate the Firm’s success as a market leader in healthcare equity financing. Mr. Chambers has consistently demonstrated the ability to both strategize and execute growth initiatives in the investment banking business and will be substantively additive to HCW’s growing prowess. His appointment is also a reflection of the Firm’s continued commitment to outpacing other middle-market broker-dealers while providing highly-effective leadership to HCW’s team of healthcare focused investment bankers.

Mr. Chambers joins HCW from Roth Capital Partners where he had been Vice Chairman and Head of Healthcare Investment Banking. In his 28-year career, Mr. Chambers has played a senior role in the Life Sciences/Healthcare Investment Banking groups at Rodman & Renshaw, Cowen, Lehman Brothers and UBS Securities.

“I am excited that John has chosen to join the leadership team at HCW,” commented Mark Viklund, Chief Executive Officer of HCW. “His extensive experience in raising capital and providing strategic advice to life sciences companies, along with his deep relationships in the sector, will further strengthen HCW’s ability to provide quality service to our corporate finance clients, across the full range of market capitalizations. HCW has been the leading placement agent in life sciences year over year and with John on the team, we will continue to increase our market share.”

Mr. Chambers added, “I have observed, with respect, the leadership position in life sciences that HCW has achieved. HCW is uniquely positioned to serve the financing and strategic efforts of a broad range of companies, from emerging growth to large cap – with the ability to service those companies throughout their growth trajectories. I am further impressed and excited about the strength of a strong and deep senior research team, which is essential to providing our institutional clients with sound investment advice. This is even more critical to our clients as we navigate the markets in the post-election environment. I am extremely proud to be a part of this leading franchise and look forward to contributing to its continued success.”

About H.C. Wainwright & Co., LLC

H.C. Wainwright & Co. is a full-service specialty investment bank dedicated to the advancement of medical breakthroughs across all areas of the Life Sciences sector. Our team is comprised of experienced scientific and financial professionals, led by industry curiosity and committed to the improvement of patients’ lives across the globe. We partner with our clients to create and implement corporate finance strategies thoughtfully tailored to benefit our mutual commitment to patients and shareholders alike. Since 2002, the HCW team has completed approximately 1,000 transactions, raising over \$23 billion for its clients. The HCW team has been the leader in the CMPO (Confidentially Marketed Public Offering), RD (Registered Direct) and PIPE (Private Investment in Public Equity) markets since 2002, completing more transactions than any other competitor. The HCW Team is ranked the Number 1 Placement Agent for the period from 2002 to 2016 by PlacementTracker. HCW also has the leading equity research team in the sector, with 10 senior analysts covering approximately 200 companies.